After grabbing 18.7 million shares, the institutional investor is now in possession of 18.7 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.88% having worth around $10.02 million. Moreover, Deep Track Capital LP increased its share by 16.23 million to have a control over 17.97 million shares. And Monaco Asset Management SAM raised its holdings to 9.26 million shares by acquiring 9.26 million shares or 4.89% of the stake.
Nektar Therapeutics (NKTR) concluded trading on 09/13/23 at a closing price of $0.69, with 3.13 million shares of worth about $2.16 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.50% during that period and on Wednesday the price saw a gain of about 4.75%. Currently the company’s common shares owned by public are about 189.66M shares, out of which, 188.10M shares are available for trading.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the NKTR stock and their offered price forecasts bring an average price target of $2.65. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $6.00 and could fall to a lowest price of $0.60. The stock’s current price level is 70.64% above of average price target set by the analysts, while a rise to estimated low would result in loss of -15.0% for the stock. However, touching the estimated high of $6.00 would mean a gain of 88.5% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 25 times over the past 12 months. They bought 71,400 shares in 7 of the transactions. In 18 selling transactions, insiders dumped 238,033 shares.
Vanguard Total Stock Market ETF, PRIMECAP Odyssey Aggressive Growt, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Nektar Therapeutics Vanguard Total Stock Market ETF is currently holding 5.85 million shares of worth totaling $3.13 million. The company recently came buying 0.0 shares which brought its stake up to 3.09% of the company’s outstanding shares. PRIMECAP Odyssey Aggressive Growt sold -2.58 million shares, after which its hold over company’s outstanding shares shrunk to 2.72%, leaving 5.15 million shares with the mutual fund that have a worth of about $2.76 million. Vanguard Extended Market Index Fu, after buying 2.68 million shares, have now control over 1.42% of the stake in the company. It holds 0.0 shares of worth $1.43 million.
However, the stock later moved at a day high price of 0.6998, or with a gain of 4.75%. Stock saw a price change of 20.42% in past 5 days and over the past one month there was a price change of -16.25%. Year-to-date (YTD), NKTR shares are showing a performance of -69.47% which decreased to -81.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.51 but also hit the highest price of $4.36 during that period. The average intraday trading volume for Nektar Therapeutics shares is 7.14 million. The stock is currently trading 5.33% above its 20-day simple moving average (SMA20), while that difference is up 7.87% for SMA50 and it goes to -49.04% lower than SMA200.
RA Capital Management LP acquired 18.7 million shares of Nektar Therapeutics having value of about $10.02 million. Nektar Therapeutics (NASDAQ: NKTR) currently have 189.66M outstanding shares and institutions hold larger chunk of about 94.80% of that. Holding of mutual funds in the company is about 3.12% while other institutional holders and individual stake holders have control over 64.32% and 19.37% of the stake respectively.
The stock has a current market capitalization of $133.85M and its 3Y-monthly beta is at 0.98. It has posted earnings per share of -$1.63 in the same period. It has Quick Ratio of 8.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NKTR, volatility over the week remained 10.70% while standing at 8.38% over the month.
Analysts are in expectations that Nektar Therapeutics (NKTR) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter EPS is -$0.18 and it is -$0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.27 which is -$0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.31 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 31.20% while it is estimated to increase by 54.00% in next year. EPS is likely to grow at an annualized rate of -7.30% for next 5-years, compared to annual growth of -32.10% made by the stock over the past 5-years.
Analysts at 6 brokerage firms have issued recommendations for the Nektar Therapeutics (NKTR)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.20. Out of those 6 Wall Street analysts, 0 recommended a “Buy” rating, while 5 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on May 10, 2023 offering a Hold rating for the stock and assigned a target price range of between $1.50 and $1 to it.
